Synairgen (SNG) ORD GBP 0.01
Synairgen plc is a drug discovery and development company. The Company’s primary focus is developing SNG001 (inhaled interferon beta) for the treatment of coronavirus disease (COVID-19) as potentially the host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs. The Company is also engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma chronic obstructive pulmonary disease (COPD). The Company is developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta for the treatment of severe viral lung infections. The Company offers a range of products, including Cablivi, Orthoclone OKT3, Remicade and ReoPro. The Company uses its human biology BioBank platform to discover and develop therapies for respiratory disease. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.